ESMO Media Releases

Preliminary safety results from the PERUSE study presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria, open the door for the taxanes nab-paclitaxel and paclitaxel to be used in HER2-positive patients with metastatic breast cancer

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck’s comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.

Access to quality cancer care is still a big issue in Europe, and there is great heterogeneity in the availability of drugs, screening programmes and resources among countries. Neglected cancer populations exist with lower rates of early diagnosis and treatment compliance

The international community of high-standard palliative programmes is growing as the prestigious title is accredited to 18 new cancer centres

ESMO Open is dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The first articles will be published in January 2016.

New award will will acknowledge someone who has actively worked to sensitise organisations to perceive the female oncology workforce as a valuable resource

We are pleased to announce the winners of the ESMO Award, ESMO Lifetime Achievement Award and Hamilton Fairley Award

The course aims to attract medical students to the medical oncology profession to ensure there are sufficient numbers to care for the rising numbers of cancer patients

Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody

Researchers announced that the phase IIIb CONSIGN study has confirmed the benefit, with safety profile and progression free survival similar to phase III trial results

The multicentre, open label, randomised phase III trial evaluated the NK1 antagonist aprepitant for the prevention of nausea and vomiting induced by oxaliplatin-based chemotherapy in Japanese patients with colorectal cancer

A total of 6,128 patients were included in the analysis, which showed that patients with the lowest BMI had a significantly shorter overall survival than patients in the other BMI categories